Eurofins-Cerep Past Earnings Performance
Past criteria checks 2/6
Eurofins-Cerep has been growing earnings at an average annual rate of 25.8%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 13.9% per year. Eurofins-Cerep's return on equity is 11.8%, and it has net margins of 17.3%.
Key information
25.8%
Earnings growth rate
n/a
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 13.9% |
Return on equity | 11.8% |
Net Margin | 17.3% |
Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses Breakdown
How Eurofins-Cerep makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 44 | 8 | 14 | 0 |
31 Dec 22 | 48 | 12 | 13 | 0 |
30 Sep 22 | 47 | 11 | 13 | 0 |
30 Jun 22 | 46 | 11 | 12 | 0 |
31 Mar 22 | 44 | 10 | 12 | 0 |
31 Dec 21 | 42 | 10 | 12 | 0 |
30 Sep 21 | 39 | 9 | 11 | 0 |
30 Jun 21 | 36 | 8 | 11 | 0 |
31 Mar 21 | 35 | 7 | 11 | 0 |
31 Dec 20 | 33 | 6 | 11 | 0 |
30 Sep 20 | 33 | 6 | 11 | 0 |
30 Jun 20 | 33 | 6 | 10 | 0 |
31 Mar 20 | 32 | 5 | 10 | 0 |
31 Dec 19 | 31 | 4 | 10 | 0 |
30 Sep 19 | 29 | 4 | 9 | 0 |
30 Jun 19 | 27 | 3 | 9 | 0 |
31 Mar 19 | 26 | 3 | 9 | 0 |
31 Dec 18 | 25 | 4 | 9 | 0 |
30 Sep 18 | 25 | 4 | 8 | 0 |
30 Jun 18 | 24 | 4 | 8 | 0 |
31 Mar 18 | 24 | 4 | 8 | 0 |
31 Dec 17 | 24 | 4 | 8 | 0 |
30 Sep 17 | 24 | 3 | 8 | 0 |
30 Jun 17 | 25 | 3 | 8 | 0 |
31 Mar 17 | 24 | 3 | 8 | 0 |
31 Dec 16 | 24 | 2 | 8 | 0 |
30 Sep 16 | 24 | 3 | 8 | 0 |
30 Jun 16 | 24 | 3 | 8 | 0 |
31 Mar 16 | 23 | 3 | 8 | 0 |
31 Dec 15 | 23 | 2 | 8 | 0 |
30 Sep 15 | 21 | 1 | 8 | 0 |
30 Jun 15 | 20 | 0 | 8 | 0 |
31 Mar 15 | 19 | 0 | 8 | 0 |
31 Dec 14 | 19 | 0 | 8 | 0 |
30 Sep 14 | 19 | 0 | 8 | 0 |
30 Jun 14 | 19 | 0 | 8 | 0 |
31 Mar 14 | 19 | 0 | 8 | 0 |
31 Dec 13 | 19 | 0 | 9 | 0 |
Quality Earnings: ALECR has high quality earnings.
Growing Profit Margin: ALECR's current net profit margins (17.3%) are lower than last year (24.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALECR's earnings have grown significantly by 25.8% per year over the past 5 years.
Accelerating Growth: ALECR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ALECR had negative earnings growth (-33.7%) over the past year, making it difficult to compare to the Life Sciences industry average (5.4%).
Return on Equity
High ROE: ALECR's Return on Equity (11.8%) is considered low.